Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

8 Jan 2021

Abstract excerpt

The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir). To provide insights into HBV dynamics under ARC-520 treatment and its efficacy in blocking HBV DNA, HBsAg, and HBeAg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33420293
DOI: 10.1038/s41598-020-80594-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infectionPMID 33420293Read ↗

What drives the dynamics of HBV RNA during treatment?Semantic proximity Read ↗

Modeling complex decay profiles of hepatitis B virus during antiviral therapy†‡Semantic proximity Read ↗

The half-life of hepatitis B virionsSemantic proximity Read ↗

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Semantic proximity Read ↗

Anti-hepatitis B virus treatment guided by long-term virus kinetics stepwise tracing.Semantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis BSemantic proximity Read ↗

Multiphasic hepatitis B virus kinetic patterns in humanized chimeric mice can be explained via stochastic agent-based modeling of intracellular virion production cyclesSemantic proximity Read ↗

Mathematical model analysis and numerical simulation of intervention strategies to reduce transmission and re-activation of hepatitis B diseaseSemantic proximity Read ↗

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.Semantic proximity Read ↗

Mathematical investigation of HBeAg seroclearance.Semantic proximity Read ↗

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.